{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:36:05Z","timestamp":1760747765147,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.ejca.2019.08.029","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T12:29:23Z","timestamp":1569587363000},"page":"109-112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["BRAF exon 11 mutant melanoma and sensitivity to BRAF\/MEK inhibition: Two case reports"],"prefix":"10.1016","volume":"121","author":[{"given":"Audrey","family":"Melin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilie","family":"Routier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hubert","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etienne","family":"Rouleau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"20","key":"10.1016\/j.ejca.2019.08.029_bib1","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ejca.2019.08.029_bib2","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ejca.2019.08.029_bib3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S1470-2045(18)30142-6","article-title":"Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2019.08.029_bib4","unstructured":"cBioPortal for cancer genomics [Internet]. [cited 2019 Mar 11]."},{"key":"10.1016\/j.ejca.2019.08.029_bib5","unstructured":"cBioPortal for cancer genomics: BRAF in melanoma (TCGA) [Internet]. [cited 2019 Apr 14]."},{"issue":"6892","key":"10.1016\/j.ejca.2019.08.029_bib6","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ejca.2019.08.029_bib7","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR project GENIE: powering precision medicine through an international consortium","volume":"7","author":"AACR Project GENIE Consortium","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.ejca.2019.08.029_bib8","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/bjd.15436","article-title":"Beyond the BRAFV600E hotspot: biology and clinical implications of rare BRAF gene mutations in melanoma patients","volume":"177","author":"Richtig","year":"2017","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.ejca.2019.08.029_bib9","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S1535-6108(04)00087-X","article-title":"Oncogenic B-Raf mutations: crystal clear at last","volume":"5","author":"Dhillon","year":"2004","journal-title":"Cancer Cell"},{"issue":"24","key":"10.1016\/j.ejca.2019.08.029_bib10","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","article-title":"Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations","volume":"37","author":"Dankner","year":"2018","journal-title":"Oncogene"},{"issue":"7666","key":"10.1016\/j.ejca.2019.08.029_bib11","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nature23291","article-title":"Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS","volume":"548","author":"Yao","year":"2017","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.ejca.2019.08.029_bib12","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1200\/JCO.2012.46.1061","article-title":"Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma","volume":"31","author":"Bahadoran","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2019.08.029_bib13","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/CMR.0000000000000398","article-title":"Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E","volume":"27","author":"Hallmeyer","year":"2017","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.ejca.2019.08.029_bib14","doi-asserted-by":"crossref","first-page":"e219","DOI":"10.1016\/j.cllc.2019.02.022","article-title":"Clinical benefit from BRAF\/MEK inhibition in a double non-V600E BRAF mutant lung adenocarcinoma: a case report","volume":"20","author":"Reyes","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"24","key":"10.1016\/j.ejca.2019.08.029_bib15","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1158\/1078-0432.CCR-17-3384","article-title":"Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanomas","volume":"24","author":"Dankner","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"36","key":"10.1016\/j.ejca.2019.08.029_bib16","doi-asserted-by":"crossref","first-page":"60094","DOI":"10.18632\/oncotarget.11635","article-title":"Non-V600 BRAF mutations recurrently found in lung cancer predict sensitivity to the combination of Trametinib and Dabrafenib","volume":"8","author":"Noeparast","year":"2017","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.ejca.2019.08.029_bib17","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","article-title":"Targeting alterations in the RAF-MEK pathway","volume":"9","author":"Yaeger","year":"2019","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.ejca.2019.08.029_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s12032-016-0828-7","article-title":"Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients","volume":"33","author":"Bhaumik","year":"2016","journal-title":"Med Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2019.08.029_bib19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","article-title":"Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing","volume":"150","author":"Imielinski","year":"2012","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.ejca.2019.08.029_bib20","doi-asserted-by":"crossref","first-page":"E748","DOI":"10.1073\/pnas.1320956111","article-title":"Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer","volume":"111","author":"Lin","year":"2014","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919304988?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804919304988?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:25:45Z","timestamp":1760732745000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804919304988"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":20,"alternative-id":["S0959804919304988"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2019.08.029","relation":{},"ISSN":["0959-8049"],"issn-type":[{"type":"print","value":"0959-8049"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"BRAF exon 11 mutant melanoma and sensitivity to BRAF\/MEK inhibition: Two case reports","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2019.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}